Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Ulifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ulifloxacin SCHEMBL1149353 | 1.00 | LMNA (0.60) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1149423 | 1.00 | LMNA (0.60) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1149252 | 0.97 | LMNA (0.61) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1148757 | 0.95 | LMNA (0.64) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1149364 | 0.95 | LMNA (0.64) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL29360160 | 0.95 | LMNA (0.64) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1148819 | 0.95 | LMNA (0.64) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1148707 | 0.94 | LMNA (0.63) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1148491 | 0.90 | LMNA (0.59) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Ulifloxacin SCHEMBL1149416 | 0.90 | LMNA (0.59) | LMNAPIM1GSK3AGSK3BPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258705-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD GUANGZHOU BAIYUNSHAN PHARMACEUTICA FACTORY (CN) | 2014-06-18 | — | — | EP | disclosed |
| US-20110028444-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS | GUANGZHOU PHARMACEUTICAL INDUSTRY ACADEME (CN) | 2011-02-03 | — | — | US | disclosed |
| EP-2258705-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND | Guangzhou Baiyunshan Pharmaceutical Co. Ltd. Guangzhou Baiyunshan Pharmaceutica Factory (CN) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028444-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS | GLS, ATP6V1B1, CUTA | DRD3 3315/4885LMNA 4301/4885PIM1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.